<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662010</url>
  </required_header>
  <id_info>
    <org_study_id>15-2029</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02662010</nct_id>
  </id_info>
  <brief_title>The Relationship Between Advanced Glycation Endproducts and Diabetes</brief_title>
  <official_title>The Relationship of Advanced Glycation Endproducts in the Anterior Lens Capsule to Glycemic Status and Diabetic Retinopathy: A Cross Sectional Study of Patients With and Without Type 2 Diabetes Mellitus Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this COMIRB application is to perform a cross-sectional pilot study to
      aid in the design of a prospective epidemiologic study for an NIH grant application. The long
      term goal of this research is to determine if AGEs are predictors of glycemic control and the
      development of diabetic retinopathy in patients with T2DM. Understanding these relationships
      could lead to a prospective prediction of the onset/worsening of diabetic retinopathy in T2DM
      patients and in pre-diabetic individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Below are the specific aims and research hypotheses for the pilot study:

      Specific Aim 1: To successfully recruit 80 subjects (40 with no diabetes, 20 with diabetes
      and no diabetic retinopathy and 20 with diabetes and diabetic retinopathy) and obtain
      adequate samples (blood and lens capsule) for further testing.

      Hypothesis 1:

      Recruitment of subjects with and without diabetes and diabetic retinopathy is feasible within
      our clinic and the process for collecting, processing and storing samples is adequate to
      support the full study.

      Specific Aim 2: To measure anterior lens capsule AGEs and HbA1c levels in recruited patients.

      Hypothesis 2:

      Levels of AGEs and HbA1c will be quantifiable in collected samples.

      The pilot study aims are necessary to determine the feasibility of the full study, as well as
      to provide estimates of the (1) proportion of non-diabetic subjects with Abnormal HbA1c, (2)
      effect sizes and (3) variances for planning the full study.

      The planned specific aims and research hypotheses for the full study are as follows:

      Specific Aim 1: To determine whether anterior lens capsule AGEs differ in patients with and
      without a clinical diagnosis of T2DM.

      Hypothesis 1:

      Levels of AGEs will be higher in patients with a clinical diagnosis of T2DM compared with
      patients without a clinical diagnosis of diabetes.

      Specific Aim 2: To determine if levels of AGEs measured from the anterior lens capsule are
      correlated with levels of Hemoglobin A1c (HbA1c) in patients without T2DM.

      Hypothesis 2:

      Levels of HbA1c will positively correlate with levels of HbA1c in all patients.

      Specific Aim 3: To determine among patients with T2DM if levels of AGEs measured from the
      anterior lens capsule are higher in the group with diabetic retinopathy compared with the
      group with no diabetic retinopathy.

      Hypothesis 3:

      That among patients with T2DM: Levels of AGEs will be higher in the patients with diabetic
      retinopathy compared with the patients with no diabetic retinopathy.

      AGEs are elevated in patients with diabetes (1, 3) and are reported to have a role in
      diabetic complications. (4, 5) Hyperglycemia results in higher intracellular glucose levels
      and the formation of metabolites from many complex interactions which in turn increase the
      production of AGEs. AGEs are a source of reactive oxygen species (ROS) with results in
      oxidative stress to tissues.(4) As reported, oxidative stress plays an important role in the
      microvascular and cardiovascular pathologic processed described in T2DM. (6) Importantly,
      oxidative stress is causal in the development of b cell dysfunction and insulin resistance,
      the two hallmarks of T2DM. (4)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Advanced Glycation Endproducts (AGE) Levels</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C Levels</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buffy Coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Investigators propose recruiting 80 subjects (40 with no diabetes, 20 with diabetes and
        no diabetic retinopathy and 20 with diabetes and diabetic retinopathy).

        Within the 40 control patients without a clinical diagnosis of T2DM, 20 will have an
        abnormal HbA1C at the time of surgery. It is important to enroll the patients with an
        abnormal HbA1C in order to see if there are early manifestations of an abnormal glucose
        level as detected by AGEs in the anterior lens capsule.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria (cases):

          -  T2DM as documented by the referring physician, an HbA1C level of greater than 5.7
             mmol/mol, or on T2DM medications beyond Metformin.

          -  50% of the cases will have diabetic retinopathy as documented by the attending
             ophthalmologist and 50% will have no retinopathy.

          -  Age 60-80 years old.

        Inclusion criteria (controls):

          1. Normal HbA1C

               -  No diabetes as documented by the referring physician, a HbA1C level of less than
                  or equal to 5.7 mmol/mol, or not taking medications for T2DM with the exception
                  of Metformin.

               -  Age 60-80 years old.

          2. Abnormal HbA1C

               -  No diabetes as documented by the referring physician, a HbA1C level between 5.7
                  and 6.5 mmol/mol, and not taking medications for T2DM with the exception of
                  Metformin.

               -  Age 60-80 years old.

        Exclusion criteria (cases):

          -  Type 1 diabetes as documented by the referring physician.

          -  &lt;60 years old or &gt;80 years old.

          -  If the patient has bilateral cataract surgery, the second surgery will be excluded

          -  Patients who have active cancer, being treated (receiving Chemotherapy or Radiation
             therapy) or disseminated, recent CVD event, MI or CVA within 6 months, and disease
             related weight loss of more than 10% in the past 3-6 months.

        Exclusion criteria (controls):

          -  Type 1 or T2DM as documented by the referring physician.

          -  &lt;60 years old or &gt;80 years old.

          -  No treatment with Metformin or modifiers for risk of T1DM

          -  If the patient has bilateral cataract surgery, the second surgery will be excluded

          -  Patients who have active cancer, being treated (receiving Chemotherapy or Radiation
             therapy) or disseminated, recent CVD event, MI or CVA within 6 months, and disease
             related weight loss of more than 10% in the past 3-6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ram Nagaraj, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Levi Bonnell</last_name>
    <phone>3038483059</phone>
    <email>levi.bonnell@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universtiy of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Levi Bonnell, MPH</last_name>
      <phone>303-848-5039</phone>
      <email>levi.bonnell@ucdenver.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Milne R, Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids. 2013 Jun;44(6):1397-407. doi: 10.1007/s00726-011-1071-3. Epub 2011 Sep 11. Review.</citation>
    <PMID>21909978</PMID>
  </reference>
  <reference>
    <citation>Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1-21. Review.</citation>
    <PMID>11237208</PMID>
  </reference>
  <reference>
    <citation>Yan SF, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes &amp; aging. Curr Mol Med. 2007 Dec;7(8):699-710. Review.</citation>
    <PMID>18331228</PMID>
  </reference>
  <reference>
    <citation>Nowotny K, Jung T, HÃ¶hn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015 Mar 16;5(1):194-222. doi: 10.3390/biom5010194. Review.</citation>
    <PMID>25786107</PMID>
  </reference>
  <reference>
    <citation>Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci. 2005 Jun;1043:567-81. Review.</citation>
    <PMID>16037280</PMID>
  </reference>
  <reference>
    <citation>Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545. Review.</citation>
    <PMID>21030723</PMID>
  </reference>
  <reference>
    <citation>Smuda M, Henning C, Raghavan CT, Johar K, Vasavada AR, Nagaraj RH, Glomb MA. Comprehensive analysis of maillard protein modifications in human lenses: effect of age and cataract. Biochemistry. 2015 Apr 21;54(15):2500-7. doi: 10.1021/bi5013194. Epub 2015 Apr 7.</citation>
    <PMID>25849437</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AGEs</keyword>
  <keyword>glycemic control</keyword>
  <keyword>T2DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

